Data from a number of recently completed major clinical trials have helped clarify questions regarding the best treatment approaches for patients who have had a myocardial infarction (MI), as well as providing information concerning the safety and efficacy of several new antithrombotic agents. These results were presented at the 45th Scientific Session of the American College of Cardiology [Florida, US; March 1996]